No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
JBM (Healthcare) Unit to Buy 90% Stake in Medicine Maker
Hong Kong stock announcement for treasure hunting | STANCHART (02888) released its full-year performance for 2024, with revenue increasing by 14% year-on-year to 19.7 billion USD, setting a historical high.
Great Wall Motor (02333) plans to acquire the remaining 80% stake in Wuxi Xindong to enhance industry synergy and overall competitiveness……
Gelonghui Announcement Highlights (Hong Kong Stocks) | CHINA RE (01508.HK) Profit Upgrade: Expected net income growth of approximately 80% to 100% for the 2024 fiscal year.
【Today's Focus】CHINA RE (01508.HK) announces positive profit news: Expected net income growth of approximately 80% to 100% in 2024. CHINA RE (01508.HK) announced that the net income attributable to the parent company's shareholders for 2024 is expected to increase by approximately 80% to 100% compared to the same period in 2023. The main reason for the group's projected performance improvement in 2024 is the company's adherence to the operational philosophy of 'development with scale, efficient underwriting, and stable investment,' which leads to continuous improvement in underwriting performance and a year-on-year increase in investment returns. 【Significant Matters】CGN POWER (018
JBM HEALTHCARE (02161.HK) plans to acquire 90% of the equity of Tianxi Commodity Pharmaceutical Factory for 0.171 billion Hong Kong dollars.
On February 21, Gelonghui reported that JBM HEALTHCARE (02161.HK) announced that on February 21, 2025, the buyer (a wholly-owned subsidiary of the company) entered into a sales agreement with the seller, according to which the buyer conditionally agreed to acquire and the seller conditionally agreed to sell shares (accounting for 90% of the issued share capital of the target company, Tianxitang Pharmaceutical Co., Ltd.). According to the terms and conditions of the sales agreement, the total consideration is HKD 0.171 billion. The target company is a limited company registered in Hong Kong, primarily engaged in the manufacturing, promotion, and sale of the brand Traditional Chinese Medicine, Tianxitang Tianxiwang, which has a long-standing historical heritage in Hong Kong and.
Express News | JBM (Healthcare) Ltd - to Acquire 90% of Tin Hee Tong Medicine Factory for HK$171 Mln
